Centessa Pharmaceuticals plc’s launch of a phase I/IIa trial with LB-101, a PD-L1xCD47 candidate that emerged from the Lockbody platform, highlighted the firm’s efforts against solid tumors. But the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback